Chromosome Study Leads to Counseling Pregnant Women
By LabMedica International staff writers Posted on 06 Jun 2018 |
Image: A microsatellite analysis of a patient with balanced chromosomal rearrangements (Photo courtesy of Human Genetics).
Fetuses with a so-called new balanced chromosomal aberration have a higher risk of developing brain disorders such as autism and mental retardation than previously anticipated and the risk is 20% for fetuses with these types of aberrations.
These chromosomal aberrations are seen in the fetus in one out of 2,000 pregnant women. Until now, when such an aberration has been found, the medical doctors have told the pregnant woman that the fetus' risk of developing congenital malformations is 6% to 9%.
Scientists from the University of Copenhagen (Copenhagen, Denmark) performed long-term follow-up (mean 17 years) of a registry-based nationwide cohort of 41 individuals carrying a prenatally detected de novo balanced chromosomal rearrangements (BCR) with normal first trimester screening/ultrasound scan. In Danish hospitals the method of classical chromosomal analysis, where the genetic material is examined in a microscope, is increasingly being replaced with another method, chromosomal microarray.
The team examined the Danish health records to find everyone born with a de novo balanced chromosomal aberration since 1975. Each time they found a person with the aberration, they established a control group of five individuals with normal chromosomes, who had been born more or less at the same time by a mother of the same age. They then visited the majority of the persons to do a health examination and collect blood samples for modern genetic analyses. By comparing the health data of the group with the chromosomal aberrations and the control group, the scientists found two-three times higher risk of developing a neurocognitive disorder in the group with the chromosomal aberrations.
The scientists observed a significantly higher frequency of neurodevelopmental and/or neuropsychiatric disorders than in a matched control group (19.5% versus 8.3%), which was increased to 26.8% upon clinical follow-up. Chromosomal microarray of 32 carriers revealed no pathogenic imbalances, illustrating a low prognostic value when fetal ultrasound scan is normal. In contrast, mate-pair sequencing revealed disrupted genes (ARID1B, NPAS3, CELF4), regulatory domains of known developmental genes (ZEB2, HOXC), and complex BCRs associated with adverse outcomes. The team found that the new whole genome sequencing techniques are much better than any other techniques at assessing the health effect of a balanced chromosomal aberration.
Iben Bache, MD, PhD, an associate professor of Clinical Genetics, and senior author of the study said, “We have not known which analyses to use to discriminate the fetuses that will be healthy from those that will eventually develop disorders. Our study shows that by using the new sequencing technologies we can in fact discriminate in a number of cases. This may greatly affect the diagnosing and counseling of pregnant women carrying fetuses with this specific type of chromosomal aberration in the future.” The study was published on May 24, 2018, in the American Journal of Human Genetics.
Related Links:
University of Copenhagen
These chromosomal aberrations are seen in the fetus in one out of 2,000 pregnant women. Until now, when such an aberration has been found, the medical doctors have told the pregnant woman that the fetus' risk of developing congenital malformations is 6% to 9%.
Scientists from the University of Copenhagen (Copenhagen, Denmark) performed long-term follow-up (mean 17 years) of a registry-based nationwide cohort of 41 individuals carrying a prenatally detected de novo balanced chromosomal rearrangements (BCR) with normal first trimester screening/ultrasound scan. In Danish hospitals the method of classical chromosomal analysis, where the genetic material is examined in a microscope, is increasingly being replaced with another method, chromosomal microarray.
The team examined the Danish health records to find everyone born with a de novo balanced chromosomal aberration since 1975. Each time they found a person with the aberration, they established a control group of five individuals with normal chromosomes, who had been born more or less at the same time by a mother of the same age. They then visited the majority of the persons to do a health examination and collect blood samples for modern genetic analyses. By comparing the health data of the group with the chromosomal aberrations and the control group, the scientists found two-three times higher risk of developing a neurocognitive disorder in the group with the chromosomal aberrations.
The scientists observed a significantly higher frequency of neurodevelopmental and/or neuropsychiatric disorders than in a matched control group (19.5% versus 8.3%), which was increased to 26.8% upon clinical follow-up. Chromosomal microarray of 32 carriers revealed no pathogenic imbalances, illustrating a low prognostic value when fetal ultrasound scan is normal. In contrast, mate-pair sequencing revealed disrupted genes (ARID1B, NPAS3, CELF4), regulatory domains of known developmental genes (ZEB2, HOXC), and complex BCRs associated with adverse outcomes. The team found that the new whole genome sequencing techniques are much better than any other techniques at assessing the health effect of a balanced chromosomal aberration.
Iben Bache, MD, PhD, an associate professor of Clinical Genetics, and senior author of the study said, “We have not known which analyses to use to discriminate the fetuses that will be healthy from those that will eventually develop disorders. Our study shows that by using the new sequencing technologies we can in fact discriminate in a number of cases. This may greatly affect the diagnosing and counseling of pregnant women carrying fetuses with this specific type of chromosomal aberration in the future.” The study was published on May 24, 2018, in the American Journal of Human Genetics.
Related Links:
University of Copenhagen
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans